11 Einträge gefunden

1. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. Ackermann, Hanns
   7. May, Angelika

   2009 - Forschungsinformationssystem des UKE
2. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. Ackermann, Hanns
   7. May, Angelika

   2008 - Forschungsinformationssystem des UKE
3. Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. May, Angelika
   7. Knecht, Rainald

   2008 - Forschungsinformationssystem des UKE
4. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.

   1. Wagenblast, Jens
   2. Hambek, Markus
   3. Baghi, Mehran
   4. Gstöttner, Wolfgang
   5. Strebhardt, Klaus
   6. Ackermann, Hanns
   7. Knecht, Rainald

   2008 - Forschungsinformationssystem des UKE
5. Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation.

   1. Hambek, Markus
   2. Werner, Christian
   3. Baghi, Mehran
   4. Gstöttner, Wolfgang
   5. Knecht, Rainald

   2007 - Forschungsinformationssystem des UKE
6. Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy.

   1. Hambek, Markus
   2. Werner, Christian
   3. Baghi, Mehran
   4. Gstöttner, Wolfgang
   5. Knecht, Rainald

   2006 - Forschungsinformationssystem des UKE
7. EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.

   1. Knecht, Rainald
   2. Peters, Silke
   3. Hambek, Markus
   4. Solbach, Christine
   5. Baghi, Mehran
   6. Gstöttner, Wolfgang

   2005 - Forschungsinformationssystem des UKE
8. Reduction of cisplatin dosage by ZD 1839.

   1. Hambek, Markus
   2. Baghi, Mehran
   3. Strebhardt, Klaus
   4. Strebhard, Klaus
   5. Baumann, Helena
   6. Gstöttner, Wolfgang
   7. Knecht, Rainald

   2005 - Forschungsinformationssystem des UKE
9. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).

   1. Hambek, Markus
   2. Baghi, Mehran
   3. Baumaun, Helena
   4. Strebhardt, Klaus
   5. Strebhard, Klaus
   6. Adunka, Oliver
   7. Gstöttner, Wolfgang

   2005 - Forschungsinformationssystem des UKE
10. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR.

    1. Hambek, Markus
    2. Baghi, Mehran
    3. Strebhardt, Klaus
    4. Strebhard, Klaus
    5. May, Angelika
    6. Adunka, Oliver
    7. Gstöttner, Wolfgang

    2004 - Forschungsinformationssystem des UKE
11. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.

    1. Knecht, Rainald
    2. Peters, Silke
    3. Solbach, Christine
    4. Baghi, Mehran
    5. Gstöttner, Wolfgang
    6. Hambek, Markus

    2003 - Forschungsinformationssystem des UKE